Improved adipose tissue function with initiation of protease inhibitor-only ART.
Identifieur interne : 001617 ( PubMed/Corpus ); précédent : 001616; suivant : 001618Improved adipose tissue function with initiation of protease inhibitor-only ART.
Auteurs : Robert T. Maughan ; Eoin R. Feeney ; Emilie Capel ; Jacqueline Capeau ; Pere Domingo ; Marta Giralt ; Joep M A. Lange ; Praphan Phanuphak ; David A. Cooper ; Peter Reiss ; Patrick W G. MallonSource :
- The Journal of antimicrobial chemotherapy [ 1460-2091 ] ; 2016.
English descriptors
- KwdEn :
- Adult, Biopsy, DNA, Mitochondrial (analysis), Female, Gene Expression Profiling, HIV Infections (drug therapy), HIV Protease Inhibitors (adverse effects), HIV Protease Inhibitors (therapeutic use), Histocytochemistry, Humans, Male, Proteome (analysis), Subcutaneous Fat (drug effects), Subcutaneous Fat (physiology), Thailand.
- MESH :
- chemical , adverse effects : HIV Protease Inhibitors.
- chemical , analysis : DNA, Mitochondrial, Proteome.
- drug effects : Subcutaneous Fat.
- drug therapy : HIV Infections.
- physiology : Subcutaneous Fat.
- chemical , therapeutic use : HIV Protease Inhibitors.
- Adult, Biopsy, Female, Gene Expression Profiling, Histocytochemistry, Humans, Male, Thailand.
Abstract
Use of ART containing HIV PIs has previously been associated with toxicity in subcutaneous adipose tissue (SAT), potentially contributing to the development of lipodystrophy and insulin resistance. However, the effect of PIs on SAT function in ART-naive patients independent of other ART classes is unknown. This study aimed to elucidate the effect of initiating PI-only ART on SAT function in ART-naive subjects.
DOI: 10.1093/jac/dkw301
PubMed: 27516476
Links to Exploration step
pubmed:27516476Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Improved adipose tissue function with initiation of protease inhibitor-only ART.</title><author><name sortKey="Maughan, Robert T" sort="Maughan, Robert T" uniqKey="Maughan R" first="Robert T" last="Maughan">Robert T. Maughan</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland robert.maughan@ucdconnect.ie.</nlm:affiliation></affiliation></author><author><name sortKey="Feeney, Eoin R" sort="Feeney, Eoin R" uniqKey="Feeney E" first="Eoin R" last="Feeney">Eoin R. Feeney</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Capel, Emilie" sort="Capel, Emilie" uniqKey="Capel E" first="Emilie" last="Capel">Emilie Capel</name><affiliation><nlm:affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><affiliation><nlm:affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Domingo, Pere" sort="Domingo, Pere" uniqKey="Domingo P" first="Pere" last="Domingo">Pere Domingo</name><affiliation><nlm:affiliation>Infectious Diseases Unit, Hospital de la Santa Creu/Sant Pau, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Giralt, Marta" sort="Giralt, Marta" uniqKey="Giralt M" first="Marta" last="Giralt">Marta Giralt</name><affiliation><nlm:affiliation>Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Lange, Joep M A" sort="Lange, Joep M A" uniqKey="Lange J" first="Joep M A" last="Lange">Joep M A. Lange</name><affiliation><nlm:affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name><affiliation><nlm:affiliation>The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:27516476</idno><idno type="pmid">27516476</idno><idno type="doi">10.1093/jac/dkw301</idno><idno type="wicri:Area/PubMed/Corpus">001617</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001617</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Improved adipose tissue function with initiation of protease inhibitor-only ART.</title><author><name sortKey="Maughan, Robert T" sort="Maughan, Robert T" uniqKey="Maughan R" first="Robert T" last="Maughan">Robert T. Maughan</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland robert.maughan@ucdconnect.ie.</nlm:affiliation></affiliation></author><author><name sortKey="Feeney, Eoin R" sort="Feeney, Eoin R" uniqKey="Feeney E" first="Eoin R" last="Feeney">Eoin R. Feeney</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author><author><name sortKey="Capel, Emilie" sort="Capel, Emilie" uniqKey="Capel E" first="Emilie" last="Capel">Emilie Capel</name><affiliation><nlm:affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Capeau, Jacqueline" sort="Capeau, Jacqueline" uniqKey="Capeau J" first="Jacqueline" last="Capeau">Jacqueline Capeau</name><affiliation><nlm:affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Domingo, Pere" sort="Domingo, Pere" uniqKey="Domingo P" first="Pere" last="Domingo">Pere Domingo</name><affiliation><nlm:affiliation>Infectious Diseases Unit, Hospital de la Santa Creu/Sant Pau, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Giralt, Marta" sort="Giralt, Marta" uniqKey="Giralt M" first="Marta" last="Giralt">Marta Giralt</name><affiliation><nlm:affiliation>Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Lange, Joep M A" sort="Lange, Joep M A" uniqKey="Lange J" first="Joep M A" last="Lange">Joep M A. Lange</name><affiliation><nlm:affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Phanuphak, Praphan" sort="Phanuphak, Praphan" uniqKey="Phanuphak P" first="Praphan" last="Phanuphak">Praphan Phanuphak</name><affiliation><nlm:affiliation>The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand.</nlm:affiliation></affiliation></author><author><name sortKey="Cooper, David A" sort="Cooper, David A" uniqKey="Cooper D" first="David A" last="Cooper">David A. Cooper</name><affiliation><nlm:affiliation>Kirby Institute, University of New South Wales, Sydney, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Reiss, Peter" sort="Reiss, Peter" uniqKey="Reiss P" first="Peter" last="Reiss">Peter Reiss</name><affiliation><nlm:affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mallon, Patrick W G" sort="Mallon, Patrick W G" uniqKey="Mallon P" first="Patrick W G" last="Mallon">Patrick W G. Mallon</name><affiliation><nlm:affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</nlm:affiliation></affiliation></author></analytic><series><title level="j">The Journal of antimicrobial chemotherapy</title><idno type="eISSN">1460-2091</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Biopsy</term><term>DNA, Mitochondrial (analysis)</term><term>Female</term><term>Gene Expression Profiling</term><term>HIV Infections (drug therapy)</term><term>HIV Protease Inhibitors (adverse effects)</term><term>HIV Protease Inhibitors (therapeutic use)</term><term>Histocytochemistry</term><term>Humans</term><term>Male</term><term>Proteome (analysis)</term><term>Subcutaneous Fat (drug effects)</term><term>Subcutaneous Fat (physiology)</term><term>Thailand</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>DNA, Mitochondrial</term><term>Proteome</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Subcutaneous Fat</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Subcutaneous Fat</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>HIV Protease Inhibitors</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Biopsy</term><term>Female</term><term>Gene Expression Profiling</term><term>Histocytochemistry</term><term>Humans</term><term>Male</term><term>Thailand</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Use of ART containing HIV PIs has previously been associated with toxicity in subcutaneous adipose tissue (SAT), potentially contributing to the development of lipodystrophy and insulin resistance. However, the effect of PIs on SAT function in ART-naive patients independent of other ART classes is unknown. This study aimed to elucidate the effect of initiating PI-only ART on SAT function in ART-naive subjects.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27516476</PMID><DateCreated><Year>2016</Year><Month>08</Month><Day>12</Day></DateCreated><DateCompleted><Year>2017</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1460-2091</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>11</Issue><PubDate><Year>2016</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Journal of antimicrobial chemotherapy</Title><ISOAbbreviation>J. Antimicrob. Chemother.</ISOAbbreviation></Journal><ArticleTitle>Improved adipose tissue function with initiation of protease inhibitor-only ART.</ArticleTitle><Pagination><MedlinePgn>3212-3221</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Use of ART containing HIV PIs has previously been associated with toxicity in subcutaneous adipose tissue (SAT), potentially contributing to the development of lipodystrophy and insulin resistance. However, the effect of PIs on SAT function in ART-naive patients independent of other ART classes is unknown. This study aimed to elucidate the effect of initiating PI-only ART on SAT function in ART-naive subjects.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In the HIVNAT-019 study, 48 HIV-infected, ART-naive Thai adults commencing PI-only ART comprising lopinavir/ritonavir/saquinavir for 24 weeks underwent assessments of fasting metabolic parameters and body composition. In a molecular substudy, 20 subjects underwent SAT biopsies at weeks 0, 2 and 24 for transcriptional, protein, mitochondrial DNA (mtDNA) and histological analyses. ClinicalTrials.gov registration number: NCT00400738.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Over 24 weeks, limb fat increased (+416.4 g, P = 0.023), coinciding with larger adipocytes as indicated by decreased adipocyte density in biopsies (-32.3 cells/mm(2), P = 0.047) and increased mRNA expression of adipogenesis regulator PPARG at week 2 (+58.1%, P = 0.003). Increases in mtDNA over 24 weeks (+600 copies/cell, P = 0.041), decreased NRF1 mRNA expression at week 2 (-33.7%, P < 0.001) and increased COX2/COX4 protein ratio at week 24 (+288%, P = 0.038) indicated improved mitochondrial function. Despite decreased AKT2 mRNA at week 2 (-28.6%, P = 0.002) and increased PTPN1 mRNA at week 24 (+50.3%, P = 0.016) suggesting insulin resistance, clinical insulin sensitivity [by homeostasis model assessment (HOMA-IR)] was unchanged.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Initiation of PI-only ART showed little evidence of SAT toxicity, the changes observed being consistent with a return to health rather than contributing to lipodystrophy.</AbstractText><CopyrightInformation>© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Maughan</LastName><ForeName>Robert T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland robert.maughan@ucdconnect.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Feeney</LastName><ForeName>Eoin R</ForeName><Initials>ER</Initials><AffiliationInfo><Affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capel</LastName><ForeName>Emilie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Capeau</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Sorbonne Universities, UPMC Univ Paris 06, INSERM UMRS 938, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Domingo</LastName><ForeName>Pere</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Infectious Diseases Unit, Hospital de la Santa Creu/Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giralt</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Molecular Biology, University of Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER Fisiopatologia de la Obesidad y Nutrición, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lange</LastName><ForeName>Joep M A</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Phanuphak</LastName><ForeName>Praphan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Chulalongkorn University, Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Kirby Institute, University of New South Wales, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reiss</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Academic Medical Center, Department of Global Health and Division of Infectious Diseases, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The HIV-Netherlands Australia Thailand Research Collaboration (HIV-NAT) - Thai Red Cross Aids Research Center (TRCARC), Bangkok, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mallon</LastName><ForeName>Patrick W G</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>HIV Molecular Research Group, School of Medicine, University College Dublin, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>HIVNAT-019 Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00400738</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Antimicrob Chemother</MedlineTA><NlmUniqueID>7513617</NlmUniqueID><ISSNLinking>0305-7453</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004272">DNA, Mitochondrial</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017320">HIV Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020543">Proteome</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Cell. 2002 Dec 27;111(7):931-41</RefSource><PMID Version="1">12507421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72</RefSource><PMID Version="1">16284533</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2009 Jun 1;23(9):1109-18</RefSource><PMID Version="1">19417580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 1998 May 7;12(7):F51-8</RefSource><PMID Version="1">9619798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>HIV Med. 2012 Sep;13(8):505-15</RefSource><PMID Version="1">22416798</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2016 Apr 1;62(7):853-62</RefSource><PMID Version="1">26797215</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS Lett. 2005 Jan 3;579(1):41-7</RefSource><PMID Version="1">15620688</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2007 Aug 15;45(5):508-14</RefSource><PMID Version="1">17589373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2003 Oct 17;278(42):41510-8</RefSource><PMID Version="1">12902348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2007;12(8):1273-83</RefSource><PMID Version="1">18240867</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2002 Mar 23;359(9311):1026-31</RefSource><PMID Version="1">11937183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Mar 12;22(5):575-84</RefSource><PMID Version="1">18316998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Antimicrob Chemother. 2008 May;61(5):1145-53</RefSource><PMID Version="1">18285316</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2010;15(8):1125-32</RefSource><PMID Version="1">21149919</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Infect Dis. 2013 Nov;13(11):964-75</RefSource><PMID Version="1">24156897</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2003 Aug;8(4):323-31</RefSource><PMID Version="1">14518702</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):131-7</RefSource><PMID Version="1">22580565</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2014 Nov;58(11):6717-23</RefSource><PMID Version="1">25155608</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2003 Nov 21;17(17):2437-44</RefSource><PMID Version="1">14600514</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 Nov 5;18(16):2137-44</RefSource><PMID Version="1">15577646</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2012 Nov 13;26(17):2165-74</RefSource><PMID Version="1">22874517</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2006;11(6):729-40</RefSource><PMID Version="1">17310817</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Obesity (Silver Spring). 2006 Jun;14(6):994-1002</RefSource><PMID Version="1">16861604</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2002 Feb 1;29(2):117-21</RefSource><PMID Version="1">11832679</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Lipid Res. 2011 Feb;52(2):207-20</RefSource><PMID Version="1">21068005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Biol Chem. 2011 Jun 24;286(25):22047-54</RefSource><PMID Version="1">21536665</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2011 Jan 14;25(2):165-70</RefSource><PMID Version="1">21150553</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Acquir Immune Defic Syndr. 2003 May 1;33(1):22-8</RefSource><PMID Version="1">12792351</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2013 Nov 27;310(20):2191-4</RefSource><PMID Version="1">24141714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2004 Apr 30;18(7):1029-36</RefSource><PMID Version="1">15096806</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Jan 11;22(2):227-36</RefSource><PMID Version="1">18097225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2004 Feb 7;363(9407):429-38</RefSource><PMID Version="1">14962523</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2011 Oct;53(8):807-16</RefSource><PMID Version="1">21921224</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(9):e25237</RefSource><PMID Version="1">21966466</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Drug Investig. 2014 Apr;34(4):287-96</RefSource><PMID Version="1">24557728</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2003 Apr;52(4):918-25</RefSource><PMID Version="1">12663461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antimicrob Agents Chemother. 2008 May;52(5):1670-6</RefSource><PMID Version="1">18332166</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2007;12(4):489-500</RefSource><PMID Version="1">17668557</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Res Ther. 2013 Jan 24;10(1):3</RefSource><PMID Version="1">23347595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2005 May 15;191(10):1686-96</RefSource><PMID Version="1">15838796</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Antivir Ther. 2012;17(3):549-56</RefSource><PMID Version="1">22293506</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metabolism. 2005 May;54(5):561-7</RefSource><PMID Version="1">15877283</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2003 May 2;17(7):971-9</RefSource><PMID Version="1">12700446</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 1985 Jul;28(7):412-9</RefSource><PMID Version="1">3899825</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2013 Mar 27;27(6):973-9</RefSource><PMID Version="1">23698063</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004272" MajorTopicYN="N">DNA, Mitochondrial</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020869" MajorTopicYN="N">Gene Expression Profiling</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017320" MajorTopicYN="N">HIV Protease Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006651" MajorTopicYN="N">Histocytochemistry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020543" MajorTopicYN="N">Proteome</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050151" MajorTopicYN="N">Subcutaneous Fat</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013785" MajorTopicYN="N">Thailand</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Autar</LastName><ForeName>Saskia R</ForeName><Initials>SR</Initials></Investigator><Investigator ValidYN="Y"><LastName>van der Lugt</LastName><ForeName>Jasper</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avihingsanon</LastName><ForeName>Anchalee</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klungklang</LastName><ForeName>Supalak</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ubolyam</LastName><ForeName>Sasiwimol</ForeName><Initials>S</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>8</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27516476</ArticleId><ArticleId IdType="pii">dkw301</ArticleId><ArticleId IdType="doi">10.1093/jac/dkw301</ArticleId><ArticleId IdType="pmc">PMC5079304</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001617 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001617 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27516476
|texte= Improved adipose tissue function with initiation of protease inhibitor-only ART.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27516476" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |